相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Autoimmune Pulmonary Alveolar Proteinosis
Cormac McCarthy et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Inhaled granulocyte-macrophage colony stimulating factor for mild-to-moderate autoimmune pulmonary alveolar proteinosis - a six month phase II randomized study with 24 months of follow-up
Xinlun Tian et al.
ORPHANET JOURNAL OF RARE DISEASES (2020)
Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis
Bruce C. Trapnell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pulmonary alveolar proteinosis
Bruce C. Trapnell et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Shaping the future of an ultra-rare disease: unmet needs in the diagnosis and treatment of pulmonary alveolar proteinosis
Cormac McCarthy et al.
CURRENT OPINION IN PULMONARY MEDICINE (2019)
Inhaled GM-CSF for Pulmonary Alveolar Proteinosis
Ryushi Tazawa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Evolving management and patient choice in pulmonary alveolar proteinosis
Maitri Munsif et al.
LANCET RESPIRATORY MEDICINE (2018)
Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach
Anupam Kumar et al.
LANCET RESPIRATORY MEDICINE (2018)
Whole lung lavage-technical details, challenges and management of complications
Ahmed Awab et al.
JOURNAL OF THORACIC DISEASE (2017)
Sequential Granulocyte-Macrophage Colony-Stimulating Factor Inhalation after Whole-Lung Lavage for Pulmonary Alveolar Proteinosis A Report of Five Intractable Cases
Shinya Ohkouchi et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2017)
Efficacy of Whole-Lung Lavage in Treatment of Pulmonary Alveolar Proteinosis
Hai-tao Zhang et al.
AMERICAN JOURNAL OF THERAPEUTICS (2016)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
A Plasmapheresis Protocol for Refractory Pulmonary Alveolar Proteinosis
Bryan Garber et al.
LUNG (2015)
Minimum Clinically Important Difference in Diffusing Capacity of the Lungs for Carbon Monoxide Among Patients with Severe and Very Severe Chronic Obstructive Pulmonary Disease
Nobuyuki Horita et al.
COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2015)
Impaired Carbon Monoxide Diffusing Capacity is the strongest lung function predictor of decline in 12 minute-walking distance in COPD; a 5-year follow-up study
Amir Farkhooy et al.
COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2015)
Long-Term Inhaled Granulocyte Macrophage-Colony-Stimulating Factor in Autoimmune Pulmonary Alveolar Proteinosis: Effectiveness, Safety, and Lowest Effective Dose
Spyros A. Papiris et al.
CLINICAL DRUG INVESTIGATION (2014)
Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis
Francesco Bonella et al.
ORPHANET JOURNAL OF RARE DISEASES (2013)
Direct evidence that GM-CSF inhalation improves lung clearance in pulmonary alveolar proteinosis
Kazumasa Ohashi et al.
RESPIRATORY MEDICINE (2012)
Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects
Warren Lenney et al.
JOURNAL OF CYSTIC FIBROSIS (2011)
Patient-derived Granulocyte/Macrophage Colony-Stimulating Factor Autoantibodies Reproduce Pulmonary Alveolar Proteinosis in Nonhuman Primates
Takuro Sakagami et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Inhaled Granulocyte/Macrophage-Colony Stimulating Factor as Therapy for Pulmonary Alveolar Proteinosis
Ryushi Tazawa et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Updating the Minimal Important Difference for Six-Minute Walk Distance in Patients With Chronic Obstructive Pulmonary Disease
Anne E. Holland et al.
ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION (2010)
Rituximab therapy in autoimmune pulmonary alveolar proteinosis
R. Borie et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Pharmacokinetics and safety of tobramycin administered by the PARI eFlow® rapid nebulizer in cystic fibrosis
Dominique Hubert et al.
JOURNAL OF CYSTIC FIBROSIS (2009)
Human GM-CSF Autoantibodies and Reproduction of Pulmonary Alveolar Proteinosis
Takuro Sakagami et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis
Saiprakash B. Venkateshiah et al.
CHEST (2006)
Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis
ME Wylam et al.
EUROPEAN RESPIRATORY JOURNAL (2006)
Extra-pulmonary aspects of acquired pulmonary alveolar proteinosis as predicted by granulocyte-macrophage colony-stimulating factor-deficient mice
JF Seymour
RESPIROLOGY (2006)
Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis
R Tazawa et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Evaluation of the minimal important difference for the feeling thermometer and the St. George's Respiratory questionnaire in patients with chronic airflow obstruction
HJ Schunemann et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2003)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis
JF Seymour et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2001)
分享论文
